As of Q4'25, Johnson & Johnson's ROS (Return on Sales) stands at 0.21%. This latest data point reflects a moderate level of profitability compared to previous quarters within the period covered. From Q1'23 to Q4'25, the ROS trend for JNJ has been volatile, with a significant spike to 1.27% in Q3'23 followed by a sharp decline and subsequent fluctuations. After the peak, ROS dropped to 0.29% in Q4'23 and remained within the 0.15%–0.63% range through 2024 and 2025, indicating inconsistent profitability and no clear sustained growth or decline over the observed quarters.